People with acute myeloid leukemia (AML) are considered intermediate risk and could be given the option to undergo an allogeneic stem-cell transplant, says Dr. George Yaghmour, an Assistant Professor of Clinical Medicine at USC’s Keck School of Medicine.
The therapy requires healthy stem cells that are inserted into the body to replace your damaged bone marrow. Dr. Yaghmour adds that if “immediate risk” patients react well to the standard chemotherapy for AML, they do not necessarily require the transplant.
Dr. Yaghmour continued that this is the definition of remission. If there is minimal residual disease, intermediate-risk disease sometimes can be good if the response to the standard chemotherapy is good then there is no need for transplantation.